Osugacestat - Ayala Pharmaceuticals
Alternative Names: AL-101; BM-0018; BMS-906024Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Bristol-Myers Squibb
- Developer Ayala Pharmaceuticals; Bristol-Myers Squibb; M. D. Anderson Cancer Center
- Class Amides; Antineoplastics; Benzene derivatives; Benzodiazepines; Fluorinated hydrocarbons; Small molecules
- Mechanism of Action Amyloid precursor protein secretase inhibitors; Notch receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Adenoid cystic carcinoma; Triple negative breast cancer
- No development reported Fibroma; Precursor T-cell lymphoblastic leukaemia-lymphoma; Solid tumours; T-cell lymphoma
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for clinical-Phase-Unknown development in Fibroma in Unknown (IV)
- 28 Oct 2024 No recent reports of development identified for phase-I development in Adenoid-cystic-carcinoma(Late-stage disease, Metastatic disease, Neoadjuvant therapy) in USA (IV)
- 26 Mar 2024 Immunome acquires osugacestat from Ayala Pharmaceuticals